Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Soligenix, Inc. (SNGX)
USD0.37
+0.00 (+0.57%)
US NASDAQ Healthcare Biotechnology
Address
29 Emmons Drive 8540
Princeton, NJ, US
Princeton, NJ, US
CEO
Christopher J. Schaber
Website
soligenix.com
IPO
1994-04-04
CIK 812796 ISIN US8342236044
Also trades on
NASDAQ Capital Market · SNGX (USD)
NASDAQ Capital Market · SNGXW (USD)
Description
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Endorex | DOR | 2001-10-02 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.37
+0.00 (+0.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
1.84
Float Shares
10.29M
Free Float %
99.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.40% | -15.63% | -74.99% | -73.58% | -79.40% | -79.10% | -85.71% | -97.75% | -99.88% | -99.98% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
0.37
DCF (Unlevered)
1.26
+239.6%
DCF (Levered)
1.46
+292.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-54.70
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+57.0% ★ Q1'26: +73.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +444.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+212.6% Q1'26: +233.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.77M
est: 7.74M (+13.2%)
|
10.45M
est: 6.85M (+52.5%)
|
5.43M
est: 5.80M (-6.3%)
|
5.24M
est: 4.37M (+20.0%)
|
3.22M
est: 3.79M (-15.1%)
|
1.93M
est: 2.20M (-12.1%)
|
33.4K
est: 666.0K (-95.0%)
|
250.0K
est: 783.0K (-68.1%)
|
—
est: 699.2K (-100.0%)
|
—
est: 519.0K (-100.0%)
|
—
est: 800.0K (-100.0%)
|
800.0K
800.0K – 800.0K
+0.0% YoY
|
1.00M
1.00M – 1.00M
+25.0% YoY
|
—
— – —
-100.0% YoY
|
| EBITDA |
-6.86M
est: -1.55M (-343.2%)
|
-5.62M
est: -1.37M (-310.2%)
|
-7.53M
est: -1.16M (-548.7%)
|
-9.02M
est: -873.3K (-932.3%)
|
-10.05M
est: -757.6K (-1,227.0%)
|
-18.45M
est: -439.3K (-4,099.9%)
|
-12.48M
est: -11.71M (-6.6%)
|
-14.11M
est: -13.30M (-6.0%)
|
-7.67M
est: -139.8K (-5,383.1%)
|
-9.46M
est: 103.8K (-9,213.0%)
|
-11.85M
est: 160.0K (-7,503.5%)
|
160.0K
160.0K – 160.0K
+0.0% YoY
|
200.0K
200.0K – 200.0K
+25.0% YoY
|
—
— – —
-100.0% YoY
|
| EBIT |
-7.11M
est: -1.55M (-359.1%)
|
-5.71M
est: -1.37M (-316.7%)
|
-7.59M
est: -1.16M (-554.7%)
|
-9.06M
est: -873.3K (-937.3%)
|
-10.11M
est: -757.6K (-1,234.1%)
|
-18.51M
est: -439.3K (-4,114.1%)
|
-12.51M
est: -13.24M (+5.5%)
|
-14.13M
est: -15.09M (+6.4%)
|
-7.67M
est: -139.8K (-5,387.8%)
|
-9.46M
est: 103.8K (-9,218.6%)
|
-11.85M
est: 160.0K (-7,503.5%)
|
160.0K
160.0K – 160.0K
+0.0% YoY
|
200.0K
200.0K – 200.0K
+25.0% YoY
|
—
— – —
-100.0% YoY
|
| Net Income |
-7.83M
est: -1.16B (+99.3%)
|
-3.25M
est: -486.05M (+99.3%)
|
-7.15M
est: -432.26M (+98.3%)
|
-8.90M
est: -249.66M (+96.4%)
|
-9.36M
est: -191.23M (+95.1%)
|
-17.69M
est: -200.00M (+91.2%)
|
-12.55M
est: -11.46M (-9.5%)
|
-13.80M
est: -13.04M (-5.8%)
|
-6.14M
est: -19.27M (+68.1%)
|
-8.27M
est: -36.84M (+77.6%)
|
-11.08M
est: -11.10M (+0.2%)
|
-2.08M
-2.08M – -2.08M
+81.3% YoY
|
-1.30M
-1.30M – -1.30M
+37.5% YoY
|
-4.51M
-4.51M – -4.51M
-248.0% YoY
|
| SGA |
3.60M
est: 280.60M (-98.7%)
|
3.43M
est: 248.28M (-98.6%)
|
3.21M
est: 210.19M (-98.5%)
|
2.95M
est: 158.24M (-98.1%)
|
3.48M
est: 137.27M (-97.5%)
|
4.33M
est: 79.61M (-94.6%)
|
5.01M
est: 24.14M (-79.2%)
|
6.69M
est: 28.38M (-76.4%)
|
4.48M
est: 25.34M (-82.3%)
|
4.22M
est: 18.68M (-77.4%)
|
4.36M
est: 28.79M (-84.9%)
|
28.79M
28.79M – 28.79M
+0.0% YoY
|
35.99M
35.99M – 35.99M
+25.0% YoY
|
—
— – —
-100.0% YoY
|
| EPS |
-721.04
est: -696.00 (-3.6%)
|
-223.20
est: -292.80 (+23.8%)
|
-278.40
est: -260.40 (-6.9%)
|
-162.09
est: -150.40 (-7.8%)
|
-115.88
est: -115.20 (-0.6%)
|
-154.45
est: -120.48 (-28.2%)
|
-67.54
est: -69.60 (+3.0%)
|
-76.96
est: -72.00 (-6.9%)
|
-12.66
est: -11.61 (-9.0%)
|
-4.98
est: -7.10 (+29.9%)
|
-2.14
est: -2.14 (+0.0%)
|
-0.40
-0.40 – -0.40
+81.3% YoY
|
-0.25
-0.25 – -0.25
+37.5% YoY
|
-0.87
-0.87 – -0.87
-248.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.30M
OE per share TTM
-2.40
Owner's Yield
-327.34%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
29.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
17
Total invested
600.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AM Investment Partners, LLC | 13.79M | 7.38% | — | 13.79M | — | — | OO | Delaware, U.S.A. | 2010-05-18 | ↗ |
| 2 | Adam Stern | 13.79M | 7.38% | — | 13.79M | — | — | IN | Delaware, U.S.A. | 2010-05-18 | ↗ |
| 3 | Mark Friedman | 13.79M | 7.38% | — | 13.79M | — | — | IN | Delaware, U.S.A. | 2010-05-18 | ↗ |
| 4 | 20-0975900 | 8.51M | 9.94% | — | — | — | — | OO | : | 2007-02-16 | ↗ |
| 5 | John S. Clark II | 8.51M | 9.94% | — | — | — | — | IN | : | 2007-02-16 | ↗ |
| 6 | Robert W. Butts | 8.51M | 9.94% | — | — | — | — | IN | : | 2007-02-16 | ↗ |
| 7 | America S.A. | 4.07M | 5.58% | 4.07M | — | 4.07M | — | CO | Luxembourg | 2007-01-12 | ↗ |
| 8 | Cavazza | 4.07M | 5.58% | — | 4.07M | — | — | IN | Italy | 2007-01-12 | ↗ |
| 9 | Finanzaria S.p.A. | 4.07M | 5.58% | 4.07M | — | 4.07M | — | CO | Italy | 2007-01-12 | ↗ |
| 10 | Holding America, Inc. | 4.07M | 5.58% | 4.07M | — | 4.07M | — | CO | Nevada | 2007-01-12 | ↗ |
| 11 | International S.A. | 4.07M | 5.58% | 4.07M | — | 4.07M | — | CO | Luxembourg | 2007-01-12 | ↗ |
| 12 | Pharmaceuticals, Inc. | 4.07M | 5.58% | 4.07M | — | 4.07M | — | CO | Jersey | 2007-01-12 | ↗ |
| 13 | 10 | 3.53M | 9.43% | 3.53M | — | — | — | CO | Delaware | 2016-09-19 | ↗ |
| 14 | Altamont Pharmaceutical Holdings, LLC | 2.33M | 14.10% | 2.33M | — | 2.33M | — | OO | California | 2018-07-09 | ↗ |
| 15 | Hy BioPharma, Inc. | 1.61M | 7.30% | 1.61M | — | 1.61M | — | CO | Delaware | 2014-10-03 | ↗ |
| 16 | Intrexon Corporation | 1.03M | 8.50% | — | — | — | 10.00 | CO | Virginia | 2013-05-09 | ↗ |
| 17 | Randal J. Kirk | 1.03M | 8.50% | — | — | — | 10.00 | IN | United States | 2013-05-09 | ↗ |
| 18 | ( | 872.0K | 9.90% | 250.0K | — | 250.0K | — | PN | Delaware | 2017-11-07 | ↗ |
| 19 | Amir L. Ecker | 872.0K | 9.90% | 472.0K | 325.0K | — | — | IN | Delaware | 2017-11-07 | ↗ |
| 20 | Carol G. Frankenfield | 872.0K | 9.90% | 25.0K | 275.0K | — | — | IN | Delaware | 2017-11-07 | ↗ |
| 21 | (2) | 711.8K | 2.80% | — | 678.3K | — | 678.3K | IN | California | 2020-05-06 | ↗ |
| 22 | BAM Management, LLC | 489.1K | 0.22% | — | 489.1K | — | 489.1K | OO | Delaware, U.S.A. | 2012-01-30 | ↗ |
| 23 | BAM Opportunity Fund, L.P. | 489.1K | 0.22% | — | 489.1K | — | 489.1K | PN | Delaware, U.S.A. | 2012-01-30 | ↗ |
| 24 | Hal Mintz | 489.1K | 0.22% | — | 489.1K | — | 489.1K | IN | Delaware, U.S.A. | 2012-01-30 | ↗ |
| 25 | David A. Hurwitz | 345.2K | 5.81% | — | 345.2K | — | — | IN | Delaware | 2017-10-12 | ↗ |
| 26 | John T. Bird | 345.2K | 5.81% | — | 345.2K | — | — | IN | Delaware | 2017-10-12 | ↗ |
| 27 | Neil H. Koffler | 345.2K | 5.81% | — | 345.2K | — | — | IN | Delaware | 2017-10-12 | ↗ |
| 28 | Peter M. Collery | 345.2K | 5.81% | — | 345.2K | — | — | IN | Delaware | 2017-10-12 | ↗ |
| 29 | SC Fundamental LLC | 345.2K | 5.81% | — | 345.2K | — | — | OO | Delaware | 2017-10-12 | ↗ |
| 30 | SC Fundamental Value Fund, L.P. | 345.2K | 5.81% | — | 345.2K | — | — | PN | Delaware | 2017-10-12 | ↗ |
| 31 | BAM Capital, LLC | — | 0.00% | — | — | — | — | OO | Delaware, U.S.A. | 2012-01-30 | ↗ |
| 32 | BAM Opportunity Fund SPV, LLC | — | 0.00% | — | — | — | — | OO | Delaware, U.S.A. | 2012-01-30 | ↗ |
| 33 | Ross Berman | — | 0.00% | — | — | — | — | IN | Delaware, U.S.A. | 2012-01-30 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
17
-5 vs prev Q
New positions
4
Closed positions
9
Increased
9
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | SBI SECURITIES CO., LTD. | 402.00 +400.0 (+20,000.0%) | 474.00 +471.0 (+15,700.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD1.18 +0.0% | 6 qtrs — |
| 2 | PLANTE MORAN FINANCIAL ADVISORS, LLC | 209.00 +— (+0.0%) | 247.00 -33.0 (-11.8%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD2.47 -52.2% | 8 qtrs — |
| 3 | ALBION FINANCIAL GROUP /UT | 1.00 +— (+0.0%) | 2.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -41.0% | 8 qtrs — |
| 4 | IFP ADVISORS, INC | — -50.0 (-100.0%) | — -67.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 72.1K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
425.1K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+425,132
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-11 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 10,000 | 1.63 | 16.3K | 10,000 | D | ↗ |
| 2025-12-11 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 200,000 | 1.63 | 326.0K | 200,000 | D | ↗ |
| 2025-12-11 | Guarino Jonathan L. | Officer | A-Award | A | Option (Right to Buy) | 100,000 | 1.63 | 163.0K | 100,000 | D | ↗ |
| 2025-12-11 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 100,000 | 1.63 | 163.0K | 100,000 | D | ↗ |
| 2025-10-02 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 15,132 | 1.32 | 20.0K | 15,511 | D | ↗ |
| 2025-06-20 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 17,647 | 1.70 | 30.0K | 17,647 | D | ↗ |
| 2025-06-20 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 17,647 | 1.70 | 30.0K | 17,647 | D | ↗ |
| 2025-06-20 | Parks Diane L. | Director | A-Award | A | Stock Option (Right to Buy) | 17,647 | 1.70 | 30.0K | 17,647 | D | ↗ |
| 2025-06-20 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 17,647 | 1.70 | 30.0K | 17,647 | D | ↗ |
| 2024-12-12 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 8,646 | 3.47 | 30.0K | 8,646 | D | ↗ |
| 2024-12-12 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 12,000 | 3.31 | 39.7K | 12,000 | D | ↗ |
| 2024-12-12 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 45,000 | 3.31 | 149.0K | 45,000 | D | ↗ |
| 2024-12-12 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 8,646 | 3.47 | 30.0K | 8,646 | D | ↗ |
| 2024-12-12 | Parks Diane L. | Director | A-Award | A | Stock Option (Right to Buy) | 8,646 | 3.47 | 30.0K | 8,646 | D | ↗ |
| 2024-12-12 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 8,646 | 3.47 | 30.0K | 8,646 | D | ↗ |
| 2024-12-12 | Guarino Jonathan L. | Officer | A-Award | A | Option (Right to Buy) | 20,000 | 3.31 | 66.2K | 20,000 | D | ↗ |
| 2024-12-12 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 20,000 | 3.31 | 66.2K | 20,000 | D | ↗ |
| 2023-12-15 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 38,136 | 0.59 | 22.5K | 38,136 | — | ↗ |
| 2023-12-15 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 38,136 | 0.59 | 22.5K | 38,136 | — | ↗ |
| 2023-12-15 | Parks Diane L. | Director | A-Award | A | Stock Option (Right to Buy) | 38,136 | 0.59 | 22.5K | 38,136 | — | ↗ |
| 2023-12-15 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 38,136 | 0.59 | 22.5K | 38,136 | — | ↗ |
| 2023-12-08 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 75,000 | 0.67 | 50.3K | 75,000 | — | ↗ |
| 2023-12-08 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 150,000 | 0.67 | 100.5K | 150,000 | — | ↗ |
| 2023-12-08 | Guarino Jonathan L. | Officer | A-Award | A | Option (Right to Buy) | 90,000 | 0.67 | 60.3K | 90,000 | — | ↗ |
| 2023-12-08 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 90,000 | 0.67 | 60.3K | 90,000 | — | ↗ |
| 2023-05-03 | Cote Timothy R. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.42 | 21.3K | 15,000 | — | ↗ |
| 2022-12-08 | Straube Richard | Director | A-Award | A | Option (Right to Buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-12-08 | SCHABER CHRISTOPHER J | Director | A-Award | A | Option (Right to Buy) | 140,000 | 0.00 | — | 140,000 | — | ↗ |
| 2022-12-08 | Guarino Jonathan L. | Director / Officer | A-Award | A | Option (Right to Buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-12-08 | Donini Oreola | Director | A-Award | A | Option (Right to Buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-11-17 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 46,154 | 0.00 | — | 145,285 | — | ↗ |
| 2022-11-17 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 46,154 | 0.00 | — | 126,753 | — | ↗ |
| 2022-11-17 | Parks Diane L. | Director | A-Award | A | Stock Option (Right to Buy) | 46,154 | 0.00 | — | 112,504 | — | ↗ |
| 2022-11-17 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 46,154 | 0.00 | — | 129,747 | — | ↗ |
| 2022-05-18 | Straube Richard | Director | P-Purchase | A | COMMON STOCK | 8,000 | 0.50 | 4.0K | 8,000 | — | ↗ |
| 2022-05-18 | SCHABER CHRISTOPHER J | Director | P-Purchase | A | Common Stock | 20,000 | 0.44 | 8.9K | 90,095 | — | ↗ |
| 2022-01-21 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 47,315 | 0.69 | 32.6K | 47,315 | — | ↗ |
| 2022-01-21 | Guarino Jonathan L. | Officer | A-Award | A | Option (Right to Buy) | 50,000 | 0.78 | 39.0K | 50,000 | — | ↗ |
| 2022-01-03 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 60,000 | 0.69 | 41.4K | 60,000 | — | ↗ |
| 2021-12-17 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | COMMON STOCK | 7,000 | 0.74 | 5.2K | 70,095 | — | ↗ |
| 2021-12-15 | Guarino Jonathan L. | Officer | P-Purchase | A | COMMON STOCK | 1,000 | 0.70 | 700.00 | 11,000 | — | ↗ |
| 2021-12-14 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | COMMON STOCK | 10,000 | 0.73 | 7.3K | 63,095 | — | ↗ |
| 2021-12-14 | Guarino Jonathan L. | Officer | P-Purchase | A | COMMON STOCK | 10,000 | 0.71 | 7.1K | 10,000 | — | ↗ |
| 2021-12-09 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 40,000 | 0.78 | 31.2K | 40,000 | — | ↗ |
| 2021-12-09 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 60,000 | 0.78 | 46.8K | 60,000 | — | ↗ |
| 2021-12-09 | Guarino Jonathan L. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.78 | 39.0K | 50,000 | — | ↗ |
| 2021-12-09 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 70,000 | 0.78 | 54.6K | 70,000 | — | ↗ |
| 2021-09-23 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 29,126 | 1.03 | 30.0K | 29,126 | — | ↗ |
| 2021-09-23 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 29,126 | 1.03 | 30.0K | 29,126 | — | ↗ |
| 2021-09-23 | Parks Diane L. | Director | A-Award | A | Stock Option (Right to Buy) | 29,126 | 1.03 | 30.0K | 29,126 | — | ↗ |
| 2021-09-23 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 29,126 | 1.03 | 30.0K | 29,126 | — | ↗ |
| 2021-05-14 | ZELDIS JEROME B | Director | S-Sale | D | Common Stock | 3,000 | 0.90 | 2.7K | 22,917 | — | ↗ |
| 2021-01-04 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 60,000 | 1.28 | 76.8K | 60,000 | — | ↗ |
| 2020-12-10 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 40,000 | 2.34 | 93.6K | 40,000 | — | ↗ |
| 2020-12-10 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 60,000 | 2.34 | 140.4K | 60,000 | — | ↗ |
| 2020-12-10 | Guarino Jonathan L. | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.34 | 93.6K | 40,000 | — | ↗ |
| 2020-12-10 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 70,000 | 2.34 | 163.8K | 70,000 | — | ↗ |
| 2020-09-16 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 15,228 | 1.97 | 30.0K | 15,228 | — | ↗ |
| 2020-09-16 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 15,228 | 1.97 | 30.0K | 15,228 | — | ↗ |
| 2020-09-16 | Parks Diane L. | Director | A-Award | A | Stock Option (Right to Buy) | 15,228 | 1.97 | 30.0K | 15,228 | — | ↗ |
| 2020-09-16 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 15,228 | 1.97 | 30.0K | 15,228 | — | ↗ |
| 2020-06-18 | Parks Diane L. | Director | A-Award | A | Stock Option (Right to Buy) | 13,500 | 1.76 | 23.8K | 13,500 | — | ↗ |
| 2020-01-02 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 60,000 | 1.45 | 87.0K | 60,000 | — | ↗ |
| 2019-12-12 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 30,000 | 1.24 | 37.2K | 30,000 | — | ↗ |
| 2019-12-12 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 60,000 | 1.24 | 74.4K | 60,000 | — | ↗ |
| 2019-12-12 | Guarino Jonathan L. | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.24 | 12.4K | 10,000 | — | ↗ |
| 2019-12-12 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 60,000 | 1.24 | 74.4K | 60,000 | — | ↗ |
| 2019-11-19 | ZELDIS JEROME B | Director | P-Purchase | A | Common Stock | 2,000 | 0.93 | 1.9K | 22,917 | — | ↗ |
| 2019-11-19 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 10,770 | 0.93 | 10.0K | 53,095 | — | ↗ |
| 2019-09-23 | Parks Diane L. | Director | P-Purchase | A | Common Stock | 14,940 | 0.93 | 13.9K | 14,940 | — | ↗ |
| 2019-09-19 | ZELDIS JEROME B | Director | P-Purchase | A | Common Stock | 4,000 | 0.94 | 3.7K | 20,917 | — | ↗ |
| 2019-09-09 | Guarino Jonathan L. | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.97 | 38.8K | 40,000 | — | ↗ |
| 2019-09-06 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 30,928 | 0.97 | 30.0K | 30,928 | — | ↗ |
| 2019-09-06 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 30,928 | 0.97 | 30.0K | 30,928 | — | ↗ |
| 2019-09-06 | Pearson Mark E. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 30,928 | 0.97 | 30.0K | 30,928 | — | ↗ |
| 2019-09-06 | Parks Diane L. | Director | A-Award | A | Stock Option (Right to Buy) | 30,928 | 0.97 | 30.0K | 30,928 | — | ↗ |
| 2019-09-06 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 30,928 | 0.97 | 30.0K | 30,928 | — | ↗ |
| 2019-07-08 | Parks Diane L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-28 | Pearson Mark E. | Director / 10% Owner | A-Award | A | Common Stock | 78,338 | 0.71 | 55.6K | 78,338 | — | ↗ |
| 2019-04-22 | ZELDIS JEROME B | Director | P-Purchase | A | Common Stock | 10,000 | 0.73 | 7.3K | 16,917 | — | ↗ |
| 2019-04-22 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.72 | 3.6K | 42,325 | — | ↗ |
| 2019-01-02 | SCHABER CHRISTOPHER J | Officer | A-Award | A | Option (Right to Buy) | 60,000 | 0.96 | 57.6K | 60,000 | — | ↗ |
| 2018-12-13 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 40,000 | 0.97 | 38.8K | 40,000 | — | ↗ |
| 2018-12-13 | SCHABER CHRISTOPHER J | Officer | A-Award | A | Option (Right to Buy) | 60,000 | 0.97 | 58.2K | 60,000 | — | ↗ |
| 2018-12-13 | Krumeich Karen R | Officer | A-Award | A | Option (Right to Buy) | 40,000 | 0.97 | 38.8K | 40,000 | — | ↗ |
| 2018-12-13 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 40,000 | 0.97 | 38.8K | 40,000 | — | ↗ |
| 2018-10-18 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 8,700 | 1.17 | 10.2K | 37,325 | — | ↗ |
| 2018-10-17 | Pearson Mark E. | Director | P-Purchase | A | Common Stock | 170,000 | 1.16 | 197.2K | 2,500,000 | — | ↗ |
| 2018-09-27 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 17,964 | 1.67 | 30.0K | 17,964 | — | ↗ |
| 2018-09-27 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 17,964 | 1.67 | 30.0K | 17,964 | — | ↗ |
| 2018-09-27 | Pearson Mark E. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 17,964 | 1.67 | 30.0K | 17,964 | — | ↗ |
| 2018-09-27 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 17,964 | 1.67 | 30.0K | 17,964 | — | ↗ |
| 2018-09-27 | Brownlie Keith L | Director | A-Award | A | Stock Option (Right to Buy) | 17,964 | 1.67 | 30.0K | 17,964 | — | ↗ |
| 2018-08-22 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 3,530 | 1.42 | 5.0K | 28,625 | — | ↗ |
| 2018-07-20 | Pearson Mark E. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 1,500 | 1.22 | 1.8K | 1,500 | — | ↗ |
| 2018-07-02 | Pearson Mark E. | Director / 10% Owner | — | I | WARRANT (RIGHT TO BUY) | 932,000 | 2.25 | 2.10M | 0 | — | ↗ |
| 2017-12-07 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 35,000 | 2.01 | 70.4K | 35,000 | — | ↗ |
| 2017-12-07 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 80,000 | 2.01 | 160.8K | 80,000 | — | ↗ |
| 2017-12-07 | Krumeich Karen R | Officer | A-Award | A | Option (Right to Buy) | 35,000 | 2.01 | 70.4K | 35,000 | — | ↗ |
| 2017-12-07 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 35,000 | 2.01 | 70.4K | 35,000 | — | ↗ |
| 2017-11-29 | Essetifin SPA | — | P-Purchase | A | Common Stock | 16,416 | 2.12 | 34.8K | 293,510 | — | ↗ |
| 2017-06-08 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 13,100 | 2.29 | 30.0K | 13,100 | — | ↗ |
| 2017-06-08 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 13,100 | 2.29 | 30.0K | 13,100 | — | ↗ |
| 2017-06-08 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 13,100 | 2.29 | 30.0K | 13,100 | — | ↗ |
| 2017-06-08 | Brughera Marco Maria | Director | A-Award | A | Stock Option (Right to Buy) | 13,100 | 2.29 | 30.0K | 13,100 | — | ↗ |
| 2017-06-08 | Brownlie Keith L | Director | A-Award | A | Stock Option (Right to Buy) | 13,100 | 2.29 | 30.0K | 13,100 | — | ↗ |
| 2017-05-08 | KIRK RANDAL J | 10% Owner | S-Sale | D | Common Stock | 9,695 | 2.54 | 24.6K | 440,418 | — | ↗ |
| 2017-05-05 | KIRK RANDAL J | 10% Owner | S-Sale | D | Common Stock | 71,607 | 2.70 | 193.3K | 450,113 | — | ↗ |
| 2017-05-04 | KIRK RANDAL J | 10% Owner | X-InTheMoney | A | Common Stock | 250,000 | 0.80 | 200.0K | 583,334 | — | ↗ |
| 2017-03-31 | Straube Richard | Officer | A-Award | A | Option (Right to Buy) | 20,000 | 2.67 | 53.4K | 20,000 | — | ↗ |
| 2017-03-31 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 50,000 | 2.67 | 133.5K | 50,000 | — | ↗ |
| 2017-03-31 | Krumeich Karen R | Officer | A-Award | A | Option (Right to Buy) | 20,000 | 2.67 | 53.4K | 20,000 | — | ↗ |
| 2017-03-31 | Donini Oreola | Officer | A-Award | A | Option (Right to Buy) | 20,000 | 2.67 | 53.4K | 20,000 | — | ↗ |
| 2016-12-16 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 15,804 | 3.16 | 49.9K | 25,095 | — | ↗ |
| 2016-12-16 | RUBIN ROBERT J. | Director | P-Purchase | A | Common Stock | 3,165 | 3.16 | 10.0K | 4,385 | — | ↗ |
| 2016-12-16 | Brughera Marco Maria | Director | P-Purchase | A | Common Stock | 2,000 | 3.16 | 6.3K | 2,750 | — | ↗ |
| 2016-06-16 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 40,541 | 0.74 | 30.0K | 40,541 | — | ↗ |
| 2016-06-16 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 40,541 | 0.74 | 30.0K | 40,541 | — | ↗ |
| 2016-06-16 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 40,541 | 0.74 | 30.0K | 40,541 | — | ↗ |
| 2016-06-16 | Krumeich Karen R | Officer | — | D | Common Stock | 0 | 0.00 | — | 13,000 | — | ↗ |
| 2016-06-16 | Brughera Marco Maria | Director | A-Award | A | Stock Option (Right to Buy) | 40,541 | 0.74 | 30.0K | 40,541 | — | ↗ |
| 2016-06-16 | Brownlie Keith L | Director | A-Award | A | Stock Option (Right to Buy) | 40,541 | 0.74 | 30.0K | 40,541 | — | ↗ |
| 2015-12-31 | Warusz Joseph Michael | Officer | A-Award | A | Option (Right to Buy) | 55,000 | 1.13 | 62.2K | 55,000 | — | ↗ |
| 2015-12-31 | Straube Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 1.13 | 79.1K | 70,000 | — | ↗ |
| 2015-12-31 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 140,000 | 1.13 | 158.2K | 140,000 | — | ↗ |
| 2015-12-31 | Donini Oreola | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 1.13 | 79.1K | 70,000 | — | ↗ |
| 2015-12-23 | ZELDIS JEROME B | Director | P-Purchase | A | Common Stock | 2,500 | 1.27 | 3.2K | 69,166 | — | ↗ |
| 2015-12-22 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.29 | 12.9K | 85,761 | — | ↗ |
| 2015-08-31 | LAPOINTE ANTHONY GREGG | Director | M-Exempt | D | Common Stock Warrant | 25,000 | 0.30 | 7.5K | 0 | — | ↗ |
| 2015-07-01 | SCHABER CHRISTOPHER J | Director / Officer | M-Exempt | A | Common Stock | 7,143 | 0.61 | 4.4K | 82,904 | — | ↗ |
| 2015-06-18 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 19,868 | 1.51 | 30.0K | 19,868 | — | ↗ |
| 2015-06-18 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 19,868 | 1.51 | 30.0K | 19,868 | — | ↗ |
| 2015-06-18 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 19,868 | 1.51 | 30.0K | 19,868 | — | ↗ |
| 2015-06-18 | Brughera Marco Maria | Director | A-Award | A | Stock Option (Right to Buy) | 19,868 | 1.51 | 30.0K | 19,868 | — | ↗ |
| 2015-06-18 | Brownlie Keith L | Director | A-Award | A | Stock Option (Right to Buy) | 19,868 | 1.51 | 30.0K | 19,868 | — | ↗ |
| 2015-04-09 | ZELDIS JEROME B | Director | M-Exempt | D | Common Stock Warrant | 17,857 | 0.61 | 10.9K | 0 | — | ↗ |
| 2015-04-09 | Brownlie Keith L | Director | M-Exempt | A | Common Stock | 14,286 | 0.61 | 8.7K | 50,000 | — | ↗ |
| 2014-12-24 | Warusz Joseph Michael | Officer | P-Purchase | A | Common Stock Warrant | 4,959 | 1.48 | 7.3K | 4,959 | — | ↗ |
| 2014-12-24 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock Warrant | 4,959 | 1.48 | 7.3K | 4,959 | — | ↗ |
| 2014-12-22 | Warusz Joseph Michael | Officer | P-Purchase | A | Common Stock | 8,265 | 1.21 | 10.0K | 12,955 | — | ↗ |
| 2014-12-22 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 8,265 | 1.21 | 10.0K | 75,761 | — | ↗ |
| 2014-12-04 | Warusz Joseph Michael | Officer | A-Award | A | Option (Right to Buy) | 45,000 | 1.50 | 67.5K | 45,000 | — | ↗ |
| 2014-12-04 | Straube Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.50 | 75.0K | 50,000 | — | ↗ |
| 2014-12-04 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Option (Right to Buy) | 100,000 | 1.50 | 150.0K | 100,000 | — | ↗ |
| 2014-12-04 | Donini Oreola | Officer | — | D | Stock Option (Right to Buy) | 30,000 | 1.50 | 45.0K | 0 | — | ↗ |
| 2014-08-05 | Brughera Marco Maria | Director | M-Exempt | A | Common Stock | 7,500 | 2.01 | 15.1K | 7,500 | — | ↗ |
| 2014-06-19 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 13,669 | 2.19 | 29.9K | 13,669 | — | ↗ |
| 2014-06-19 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 13,669 | 2.19 | 29.9K | 13,669 | — | ↗ |
| 2014-06-19 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 13,669 | 2.19 | 29.9K | 13,669 | — | ↗ |
| 2014-06-19 | Brughera Marco Maria | Director | A-Award | A | Stock Option (Right to Buy) | 13,669 | 2.19 | 29.9K | 13,669 | — | ↗ |
| 2014-06-19 | Brownlie Keith L | Director | A-Award | A | Stock Option (Right to Buy) | 13,669 | 2.19 | 29.9K | 13,669 | — | ↗ |
| 2014-05-19 | Warusz Joseph Michael | Officer | M-Exempt | D | Option (Right to Buy) | 4,690 | 0.64 | 3.0K | 25,310 | — | ↗ |
| 2014-05-14 | Brownlie Keith L | Director | M-Exempt | A | Common Stock | 16,667 | 0.30 | 5.0K | 35,714 | — | ↗ |
| 2014-05-13 | SCHABER CHRISTOPHER J | Director / Officer | M-Exempt | D | Option (Right to Buy) | 7,815 | 0.64 | 5.0K | 112,185 | — | ↗ |
| 2014-01-06 | Straube Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.01 | 201.0K | 100,000 | — | ↗ |
| 2013-12-05 | Warusz Joseph Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 2.01 | 90.5K | 45,000 | — | ↗ |
| 2013-12-05 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.01 | 201.0K | 100,000 | — | ↗ |
| 2013-12-05 | Donini Oreola | Officer | — | D | Stock Option (Right to Buy) | 20,000 | 2.01 | 40.2K | 0 | — | ↗ |
| 2013-12-05 | Brughera Marco Maria | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.01 | 30.2K | 15,000 | — | ↗ |
| 2013-12-05 | BREY ROBERT N | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.01 | 20.1K | 10,000 | — | ↗ |
| 2013-09-27 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 13,275 | 2.26 | 30.0K | 13,275 | — | ↗ |
| 2013-09-27 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 13,275 | 2.26 | 30.0K | 13,275 | — | ↗ |
| 2013-09-27 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 13,275 | 2.26 | 30.0K | 13,275 | — | ↗ |
| 2013-09-27 | Brownlie Keith L | Director | A-Award | A | Stock Option (Right to Buy) | 13,275 | 2.26 | 30.0K | 13,275 | — | ↗ |
| 2013-09-25 | Warusz Joseph Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 0.68 | 37.4K | 55,000 | — | ↗ |
| 2013-09-25 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 0.68 | 88.4K | 130,000 | — | ↗ |
| 2013-09-25 | HORGAN KEVIN | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 0.68 | 57.8K | 85,000 | — | ↗ |
| 2013-09-25 | BREY ROBERT N | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 0.68 | 23.8K | 35,000 | — | ↗ |
| 2013-08-15 | Donini Oreola | Officer | — | D | Stock Option (Right to Buy) | 40,000 | 1.56 | 62.4K | 0 | — | ↗ |
| 2013-06-25 | ZELDIS JEROME B | Director | P-Purchase | A | Common Stock | 23,809 | 1.05 | 25.0K | 48,809 | — | ↗ |
| 2013-06-25 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 9,523 | 1.05 | 10.0K | 59,681 | — | ↗ |
| 2013-06-25 | Brownlie Keith L | Director | P-Purchase | A | Common Stock | 19,047 | 1.05 | 20.0K | 19,047 | — | ↗ |
| 2013-06-20 | ZELDIS JEROME B | Director | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 0.30 | 7.5K | 0 | — | ↗ |
| 2013-06-20 | KIRK RANDAL J | 10% Owner | — | I | Warrant to Purchase Common Stock | 2,500,000 | 1.65 | 4.13M | 0 | — | ↗ |
| 2012-12-20 | SIGMA TAU FINANZIARIA SPA | 10% Owner | J-Other | A | Common Stock Warrant (right to buy) | 1 | 0.53 | 0.53 | 1 | — | ↗ |
| 2012-12-20 | CAVAZZA PAOLO | 10% Owner | J-Other | A | Common Stock Warrant (warrant to buy) | 1 | 0.53 | 0.53 | 1 | — | ↗ |
| 2012-06-21 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.30 | 7.5K | 25,000 | — | ↗ |
| 2012-06-21 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.30 | 7.5K | 25,000 | — | ↗ |
| 2012-06-21 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.30 | 7.5K | 25,000 | — | ↗ |
| 2012-06-21 | Brownlie Keith L | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.30 | 7.5K | 25,000 | — | ↗ |
| 2012-04-10 | SCHABER CHRISTOPHER J | Director / Officer | P-Purchase | A | Common Stock | 9,900 | 0.51 | 5.0K | 50,157 | — | ↗ |
| 2012-01-16 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Common Stock | 333,333 | 0.00 | — | 805,150 | — | ↗ |
| 2011-12-01 | Warusz Joseph Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 0.03 | 19.2K | 600,000 | — | ↗ |
| 2011-12-01 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,400,000 | 0.03 | 76.8K | 2,400,000 | — | ↗ |
| 2011-12-01 | MYRIANTHOPOULOS EVAN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,200,000 | 0.03 | 38.4K | 1,200,000 | — | ↗ |
| 2011-12-01 | HORGAN KEVIN | Officer | A-Award | A | Stock Option (Right to Buy) | 1,200,000 | 0.03 | 38.4K | 1,200,000 | — | ↗ |
| 2011-12-01 | BREY ROBERT N | Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 0.03 | 22.4K | 700,000 | — | ↗ |
| 2011-06-22 | ZELDIS JEROME B | Director | A-Award | A | Stock Option (Right to Buy) | 300,000 | 0.20 | 59.7K | 300,000 | — | ↗ |
| 2011-06-22 | THOMPSON VIRGIL | Director | A-Award | A | Stock Option (Right to Buy) | 191,722 | 0.20 | 38.2K | 191,722 | — | ↗ |
| 2011-06-22 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 191,722 | 0.20 | 38.2K | 191,722 | — | ↗ |
| 2011-06-22 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 191,722 | 0.20 | 38.2K | 191,722 | — | ↗ |
| 2011-06-22 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (Right to Buy) | 191,722 | 0.20 | 38.2K | 191,722 | — | ↗ |
| 2011-06-22 | Brownlie Keith L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-05-31 | Warusz Joseph Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 800,000 | 0.21 | 164.0K | 0 | — | ↗ |
| 2011-01-31 | HORGAN KEVIN | Officer | A-Award | A | Stock Option (Right to Buy) | 1,250,000 | 0.17 | 215.0K | 1,250,000 | — | ↗ |
| 2010-09-23 | THOMPSON VIRGIL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-09-23 | SCHNITTKER CHRISTOPHER P. | Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 0.23 | 162.4K | 700,000 | — | ↗ |
| 2010-09-23 | SCHABER CHRISTOPHER J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,200,000 | 0.23 | 510.4K | 2,200,000 | — | ↗ |
| 2010-09-23 | RUBIN ROBERT J. | Director | A-Award | A | Stock Option (Right to Buy) | 150,000 | 0.21 | 30.8K | 150,000 | — | ↗ |
| 2010-09-23 | MYRIANTHOPOULOS EVAN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,050,000 | 0.23 | 243.6K | 1,050,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
10.31M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2003 | Ralph Ellison President CEO | 200.0K | — | — | 2.00M | — | — | 200.0K | 1,000.00% | ↗ |
| 2 | 2003 | Robert Brey Chief Science Officer | 155.0K | — | — | — | — | — | 155.0K | 0.00% | ↗ |
| 3 | 2003 | David Kent, Former President CEO | 103.1K | — | — | 200.0K | — | — | 103.1K | 193.94% | ↗ |
| 4 | 2002 | Robert Brey Chief Science Officer | — | — | — | — | — | — | — | — | ↗ |
| 5 | 2002 | David Kent, Former President CEO | — | — | — | — | — | — | — | — | ↗ |
| 6 | 2002 | Ralph Ellison President CEO | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher J. Schaber | Chairman of the Board of Directors, Chief Executive Officer & President | 798.9K | — |
| Oreola Donini | Senior Vice President & Chief Scientific Officer | 416.8K | — |
| Jonathan L. Guarino CGMA | Senior Vice President, Chief Financial Officer & Corporate Secretary | 371.0K | male |
| Richard C. Straube | Consulting Chief Medical Officer | 169.0K | — |
| Adam T. Rumage | Senior VP of Project Management & Regulatory Affairs | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SNGX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
